623 related articles for article (PubMed ID: 28223388)
1.
Colley T; Alanio A; Kelly SL; Sehra G; Kizawa Y; Warrilow AGS; Parker JE; Kelly DE; Kimura G; Anderson-Dring L; Nakaoki T; Sunose M; Onions S; Crepin D; Lagasse F; Crittall M; Shannon J; Cooke M; Bretagne S; King-Underwood J; Murray J; Ito K; Strong P; Rapeport G
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223388
[TBL] [Abstract][Full Text] [Related]
2.
Colley T; Sehra G; Chowdhary A; Alanio A; Kelly SL; Kizawa Y; Armstrong-James D; Fisher MC; Warrilow AGS; Parker JE; Kelly DE; Kimura G; Nishimoto Y; Sunose M; Onions S; Crepin D; Lagasse F; Crittall M; Shannon J; McConville M; King-Underwood J; Naylor A; Bretagne S; Murray J; Ito K; Strong P; Rapeport G
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29439966
[TBL] [Abstract][Full Text] [Related]
3.
Kimura G; Nakaoki T; Colley T; Rapeport G; Strong P; Ito K; Kizawa Y
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630185
[TBL] [Abstract][Full Text] [Related]
4. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection.
Colley T; Sehra G; Daly L; Kimura G; Nakaoki T; Nishimoto Y; Kizawa Y; Strong P; Rapeport G; Ito K
Sci Rep; 2019 Jul; 9(1):9482. PubMed ID: 31263150
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.
Arendrup MC; Jensen RH; Cuenca-Estrella M
Antimicrob Agents Chemother; 2016 Jan; 60(1):532-6. PubMed ID: 26552973
[TBL] [Abstract][Full Text] [Related]
6. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
7. Azole resistance in canine and feline isolates of Aspergillus fumigatus.
Talbot JJ; Kidd SE; Martin P; Beatty JA; Barrs VR
Comp Immunol Microbiol Infect Dis; 2015 Oct; 42():37-41. PubMed ID: 26387063
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates.
Astvad KMT; Hare RK; Arendrup MC
Clin Microbiol Infect; 2017 Nov; 23(11):882-887. PubMed ID: 28373148
[TBL] [Abstract][Full Text] [Related]
10. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.
Özmerdiven GE; Ak S; Ener B; Ağca H; Cilo BD; Tunca B; Akalın H
J Infect Chemother; 2015 Aug; 21(8):581-6. PubMed ID: 26048062
[TBL] [Abstract][Full Text] [Related]
11. Insight into the Significance of Aspergillus fumigatus cyp51A Polymorphisms.
Garcia-Rubio R; Alcazar-Fuoli L; Monteiro MC; Monzon S; Cuesta I; Pelaez T; Mellado E
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29632011
[TBL] [Abstract][Full Text] [Related]
12. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.
Bueid A; Howard SJ; Moore CB; Richardson MD; Harrison E; Bowyer P; Denning DW
J Antimicrob Chemother; 2010 Oct; 65(10):2116-8. PubMed ID: 20729241
[TBL] [Abstract][Full Text] [Related]
13. Multi-triazole-resistant Aspergillus fumigatus infections in Australia.
Kidd SE; Goeman E; Meis JF; Slavin MA; Verweij PE
Mycoses; 2015 Jun; 58(6):350-5. PubMed ID: 25885568
[TBL] [Abstract][Full Text] [Related]
14. Azole preexposure affects the Aspergillus fumigatus population in patients.
Alanio A; Cabaret O; Sitterlé E; Costa JM; Brisse S; Cordonnier C; Bretagne S
Antimicrob Agents Chemother; 2012 Sep; 56(9):4948-50. PubMed ID: 22710122
[TBL] [Abstract][Full Text] [Related]
15. Azole susceptibility in clinical and environmental isolates of Aspergillus fumigatus from eastern Hokkaido, Japan.
Toyotome T; Fujiwara T; Kida H; Matsumoto M; Wada T; Komatsu R
J Infect Chemother; 2016 Sep; 22(9):648-50. PubMed ID: 27050399
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization of a Voriconazole-Resistant, Posaconazole-Susceptible Aspergillus fumigatus Isolate in a Lung Transplant Recipient in the United States.
Vazquez JA; Manavathu EK
Antimicrob Agents Chemother; 2016 Feb; 60(2):1129-33. PubMed ID: 26574014
[TBL] [Abstract][Full Text] [Related]
17. Aspergillus fumigatus harbouring the sole Y121F mutation shows decreased susceptibility to voriconazole but maintained susceptibility to itraconazole and posaconazole.
Lescar J; Meyer I; Akshita K; Srinivasaraghavan K; Verma C; Palous M; Mazier D; Datry A; Fekkar A
J Antimicrob Chemother; 2014 Dec; 69(12):3244-7. PubMed ID: 25125676
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal activity of a novel topical triazole PC945 against emerging yeast Candida auris.
Rudramurthy SM; Colley T; Abdolrasouli A; Ashman J; Dhaliwal M; Kaur H; Armstrong-James D; Strong P; Rapeport G; Schelenz S; Ito K; Chakrabarti A
J Antimicrob Chemother; 2019 Oct; 74(10):2943-2949. PubMed ID: 31325309
[TBL] [Abstract][Full Text] [Related]
19. Anti-fungal activity of a novel triazole, PC1244, against emerging azole-resistant Aspergillus fumigatus and other species of Aspergillus.
Colley T; Sharma C; Alanio A; Kimura G; Daly L; Nakaoki T; Nishimoto Y; Bretagne S; Kizawa Y; Strong P; Rapeport G; Ito K; Meis JF; Chowdhary A
J Antimicrob Chemother; 2019 Oct; 74(10):2950-2958. PubMed ID: 31361006
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Biochemical Study of CYP51-Mediated Azole Resistance in Aspergillus fumigatus.
Warrilow AG; Parker JE; Price CL; Nes WD; Kelly SL; Kelly DE
Antimicrob Agents Chemother; 2015 Dec; 59(12):7771-8. PubMed ID: 26459890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
